Browsing Tag
Monoclonal Antibody
16 posts
Innovent Biologics launches clinical trial for IBI3011 to target gout and inflammatory diseases in China
Find out how Innovent Biologics is targeting unmet needs in gout with IBI3011, a first-in-class anti-IL-1RAP antibody now in clinical trials. Read more.
Myelofibrosis breakthrough? Incyte’s INCA033989 delivers clinical and molecular wins
Incyte’s mutCALR antibody shows promise in myelofibrosis and ET. Find out what ASH 2025 data reveals about INCA033989’s future potential.
Can VGA039 become a once-monthly standard of care for von Willebrand disease?
Star Therapeutics' VGA039 shows strong bleeding reduction across all VWD types in Phase 1/2 trial. Discover how this monthly shot could change the standard of care.
AL-S Pharma’s AP-101 prolongs survival and delays ventilator use in ALS Phase 2 trial
AL-S Pharma’s AP-101 showed survival and biomarker gains in ALS Phase 2 study. Find out what this means as the firm prepares for Phase 3.
Etalanetug shows over 90% tau biomarker reduction in Eisai’s DIAD trial update at CTAD 2025
Eisai’s etalanetug shows up to 90% reduction in novel tau biomarker in Alzheimer’s patients. Find out how it could reshape the AD treatment landscape.
Leqembi UK approval: BioArctic, Eisai win MHRA nod for once-monthly Alzheimer’s treatment
BioArctic’s Leqembi now approved for monthly IV use in UK Alzheimer’s patients. Find out what this means for long-term treatment worldwide.
Galecto pivots to oncology with Damora Therapeutics buyout and massive $285m funding boost
Discover how Galecto’s $285 M Damora Therapeutics acquisition and new mutCALR antibody pipeline could transform myelofibrosis and thrombocythemia treatment.
Portela nears EU approval: Will Zoetis’ quarterly cat pain injection reshape veterinary care?
Zoetis earns CVMP approval recommendation for Portela , a long-acting anti-NGF antibody for feline OA pain. Learn how it could transform veterinary care.
FDA accepts first biosimilar without clinical efficacy studies: Will this redefine global biologics access?
FDA waives efficacy trials for Stelara biosimilar, opening new doors for fast-track biosimilar access. Find out how this could reshape drug affordability worldwide.
Omeros seeks EMA approval for narsoplimab to treat stem cell transplant-related TA-TMA
Omeros Corporation has submitted a Marketing Authorization Application to the EMA for narsoplimab, aiming to treat TA-TMA across Europe. Learn what’s at stake.